<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02062879</url>
  </required_header>
  <id_info>
    <org_study_id>Mueller2014</org_study_id>
    <nct_id>NCT02062879</nct_id>
  </id_info>
  <brief_title>Ketamine Patient-Controlled Analgesia for Acute Pain</brief_title>
  <official_title>Ketamine Patient-Controlled Analgesia for Acute Pain in Native Airway Multiple and Orthopedic Trauma Patients: A Randomized, Active Comparator, Blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare ketamine and hydromorphone as alternative patient-controlled
      interventions for trauma-related pain. Patients receiving ketamine PCA are expected to
      require less total and breakthrough opioid and to have similar or improved objective pain
      scores. Patients receiving ketamine are also expected to have shorter duration of
      supplemental oxygen requirement, fewer episodes of oxygen desaturation, improved pulmonary
      toilet, lower use of antiemetics, and shorter times to first bowel movement. Ketamine is
      further expected to be associated with decreased intensive care unit and hospital lengths of
      stay, faster time to maximum allowable ambulation, decreased opioid dosage at discharge, and
      lower report of chronic pain syndromes.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawals from study due to anticipated effects from study drugs
  </why_stopped>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Daily Opioid Requirement</measure>
    <time_frame>Participants will be followed for their entire hospital stay, an expected average of 1 week.</time_frame>
    <description>Daily breakthrough opioid requirement plus non-breakthrough opioid use in milligrams of morphine equivalents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breakthrough Daily Opioid Requirement</measure>
    <time_frame>Participants will be followed for their entire hospital stay, an expected average of 1 week</time_frame>
    <description>Breakthrough daily opioid requirement in milligrams of morphine equivalents/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Pain Score</measure>
    <time_frame>Participants will be followed for their entire hospital stay, an expected average of 1 week</time_frame>
    <description>Median daily pain score measures on a visual analogue scale for pain, with a range of 0 to 10. Higher scored indicate worse pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acute Pain</condition>
  <condition>Multiple Trauma</condition>
  <condition>Fractures</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine 90mg/30 mL PCA (3 mg/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydromorphone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine administered as patient-controlled analgesia.</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>Hydromorphone administered as patient-controlled analgesia.</description>
    <arm_group_label>Hydromorphone</arm_group_label>
    <other_name>Dilaudid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18 years

          -  Total Injury Severity Score greater than 9

          -  Functioning intravenous catheter present per standard of care

          -  Patient planned to receive PCA for acute pain per standard of care

          -  Patient ability to effectively use a PCA device as assessed by the primary attending
             trauma service

          -  Negative pregnancy test for women of childbearing age

        Exclusion Criteria:

          -  Body mass index greater than 35

          -  History of active psychiatric disease

          -  Acute or chronic liver or renal failure

          -  History of heart failure or coronary artery disease

          -  Patients with documented chronic pain syndrome who use opioids as maintenance
             medication in outpatient therapy

          -  Patients who abuse alcohol and are at high risk for alcohol withdrawal

          -  Intubated patients

          -  Glasgow Coma Scale score less than 13, or motor subscore less than 6

          -  Documented allergy to ketamine, hydromorphone, or lorazepam

          -  Pregnancy

          -  Incarceration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheila C Takieddine, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric W Mueller, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2014</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <results_first_submitted>July 20, 2017</results_first_submitted>
  <results_first_submitted_qc>August 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2017</results_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Sheila Takieddine</investigator_full_name>
    <investigator_title>Policy Development Specialist</investigator_title>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>trauma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Multiple Trauma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>Ketamine 90mg/30 mL PCA (3 mg/mL)
Ketamine: Ketamine administered as patient-controlled analgesia.</description>
        </group>
        <group group_id="P2">
          <title>Hydromorphone</title>
          <description>Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)
Hydromorphone: Hydromorphone administered as patient-controlled analgesia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>Ketamine 90mg/30 mL PCA (3 mg/mL)
Ketamine: Ketamine administered as patient-controlled analgesia.</description>
        </group>
        <group group_id="B2">
          <title>Hydromorphone</title>
          <description>Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)
Hydromorphone: Hydromorphone administered as patient-controlled analgesia.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="28" upper_limit="47"/>
                    <measurement group_id="B2" value="26" lower_limit="22" upper_limit="30"/>
                    <measurement group_id="B3" value="30" lower_limit="25" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" lower_limit="23.8" upper_limit="29"/>
                    <measurement group_id="B2" value="26.5" lower_limit="21.7" upper_limit="29"/>
                    <measurement group_id="B3" value="27" lower_limit="23" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Injury Severity Score</title>
          <description>The Injury Severity Score is an anatomical scoring system that correlates with morbidity and mortality. The value can range from 0 to 75. Higher values represent a worse outcome. Reference: Baker SP et al, &quot;The Injury Severity Score: a method for describing patients with multiple injuries and evaluating emergency care&quot;, J Trauma 14:187-196;1974.</description>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="22" upper_limit="33"/>
                    <measurement group_id="B2" value="28" lower_limit="26" upper_limit="29"/>
                    <measurement group_id="B3" value="29" lower_limit="26" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blunt Trauma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Penetrating Trauma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Daily Opioid Requirement</title>
        <description>Daily breakthrough opioid requirement plus non-breakthrough opioid use in milligrams of morphine equivalents</description>
        <time_frame>Participants will be followed for their entire hospital stay, an expected average of 1 week.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine 90mg/30 mL PCA (3 mg/mL)
Ketamine: Ketamine administered as patient-controlled analgesia.</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone</title>
            <description>Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)
Hydromorphone: Hydromorphone administered as patient-controlled analgesia.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Daily Opioid Requirement</title>
          <description>Daily breakthrough opioid requirement plus non-breakthrough opioid use in milligrams of morphine equivalents</description>
          <units>mg morphine equivalents/day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="4.2" upper_limit="15"/>
                    <measurement group_id="O2" value="42.5" lower_limit="31.7" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breakthrough Daily Opioid Requirement</title>
        <description>Breakthrough daily opioid requirement in milligrams of morphine equivalents/day</description>
        <time_frame>Participants will be followed for their entire hospital stay, an expected average of 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine 90mg/30 mL PCA (3 mg/mL)
Ketamine: Ketamine administered as patient-controlled analgesia.</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone</title>
            <description>Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)
Hydromorphone: Hydromorphone administered as patient-controlled analgesia.</description>
          </group>
        </group_list>
        <measure>
          <title>Breakthrough Daily Opioid Requirement</title>
          <description>Breakthrough daily opioid requirement in milligrams of morphine equivalents/day</description>
          <units>mg morphine equivalents/day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="0.63" upper_limit="19.38"/>
                    <measurement group_id="O2" value="10" lower_limit="4.38" upper_limit="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Pain Score</title>
        <description>Median daily pain score measures on a visual analogue scale for pain, with a range of 0 to 10. Higher scored indicate worse pain.</description>
        <time_frame>Participants will be followed for their entire hospital stay, an expected average of 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine 90mg/30 mL PCA (3 mg/mL)
Ketamine: Ketamine administered as patient-controlled analgesia.</description>
          </group>
          <group group_id="O2">
            <title>Hydromorphone</title>
            <description>Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)
Hydromorphone: Hydromorphone administered as patient-controlled analgesia.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Pain Score</title>
          <description>Median daily pain score measures on a visual analogue scale for pain, with a range of 0 to 10. Higher scored indicate worse pain.</description>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="4" upper_limit="7.5"/>
                    <measurement group_id="O2" value="5.3" lower_limit="3" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>Ketamine 90mg/30 mL PCA (3 mg/mL)
Ketamine: Ketamine administered as patient-controlled analgesia.</description>
        </group>
        <group group_id="E2">
          <title>Hydromorphone</title>
          <description>Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)
Hydromorphone: Hydromorphone administered as patient-controlled analgesia.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sheila Takieddine</name_or_title>
      <organization>UC Health University of Cincinnati Medical Center</organization>
      <phone>513-585-6195</phone>
      <email>Sheila.Takieddine@UCHealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

